How did the published retatrutide trial escalate to its target doses?

Participants were randomised to a target dose of 1, 4, 8 or 12 mg once weekly subcutaneously and reached it either directly or by stepwise escalation from a lower starting dose during the first months of the 48-week treatment period (NCT04881760). The individual step sequences and their timing are recorded in the trial registration and are not reproduced here; they describe randomised study arms, not an application protocol. Published as Jastreboff AM et al., N Engl J Med 2023;389(6):514-526, PMID 37366315.

Did all arms follow the same escalation?

No. The trial ran several arms: 1 mg, a 4 mg target reached either directly or from a 2 mg start, an 8 mg target reached from a 2 mg or a 4 mg start, and a 12 mg target reached from a 2 mg start (NCT04881760). The same target dose was therefore reached by different routes in different arms, a design feature of the trial rather than a choice between protocols.

Is retatrutide approved?

No. To our knowledge, as of September 2026, retatrutide holds no marketing authorisation in the EU and no FDA approval for any indication, and the sponsor stated on 23 July 2026 that it plans to submit a Biologics License Application to the FDA in the first quarter of 2027 (press release, 23 July 2026). Eli Lilly states publicly that it is not available for public use and is being studied in clinical trials. The doses identified on this page as trial doses describe investigational study arms.

How does the retatrutide schedule compare with semaglutide and tirzepatide?

On paper the shape is similar: all three start low, escalate stepwise and dose once weekly. The step lengths are specified in the approved prescribing information for semaglutide and tirzepatide and, for retatrutide, in the Phase 2 trial registration; this page does not reproduce them side by side. The comparison is a comparison of schedule shape only, drawn from approved labels alongside a published trial regimen for an investigational compound. It is not an efficacy or safety ranking, and no head-to-head trial of retatrutide against either compound has reported results; two are registered and active and not recruiting, one against tirzepatide in an estimated 800 participants over 80 weeks (NCT06662383) and one against semaglutide in an estimated 1,250 participants over 80 weeks (NCT06260722), neither with posted results (ClinicalTrials.gov, query retatrutide, 2026-09-18).

Why are retatrutide's trial doses numerically higher than semaglutide's? Is it a stronger drug?

No, and this is a common misreading. Milligram numbers are not comparable across different molecules: they reflect potency per milligram, molecular weight and formulation, not how powerful a compound is. Comparing 12 mg of one peptide with 2.4 mg of another tells you nothing about their relative effect.

What is known about retatrutide pharmacokinetics?

The Phase 1b multiple-ascending-dose trial in people with type 2 diabetes (Urva S et al., Lancet 2022;400(10366):1869-1881, PMID 36354040) established the pharmacokinetic basis for once-weekly dosing. The compound carries a fatty-acid side chain that binds albumin, which extends its elimination half-life to roughly six days and is what makes a weekly schedule feasible.

What were the main side effects at these doses?

Gastrointestinal effects dominate and are dose-related: nausea, diarrhoea, vomiting and constipation, mostly mild to moderate in the Phase 2 report. A sensory effect, dysaesthesia, appeared in the later TRIUMPH-4 sponsor topline at 8.8% (9 mg) and 20.9% (12 mg) against 0.7% on placebo. We cover the safety profile in detail in a separate article.

How long did the Phase 2 trial run and how many people took part?

The trial enrolled 338 adults and had a 48-week treatment period. It was a randomised, placebo-controlled Phase 2 trial in obesity, funded by Eli Lilly, registered as NCT04881760 and published in the New England Journal of Medicine in 2023 (PMID 37366315).

What weight changes were reported at each dose?

At 48 weeks the least-squares mean change in body weight was -8.7% at 1 mg, -17.1% in the combined 4 mg group, -22.8% in the combined 8 mg group and -24.2% at 12 mg, against -2.1% on placebo. In the same Phase 2 obesity trial (338 adults, 48 weeks, PMID 37366315), at least 5 percent weight loss was reached by 100 percent of the 12 mg group versus 27 percent of placebo. The dose-response is clear across the arms.

Are the Phase 3 TRIUMPH results published?

The TRIUMPH results are not. The TRIUMPH programme's rationale and design were published peer-reviewed (Diabetes Obes Metab 2026, PMID 41090431), and one Phase 3 trial outside that programme, TRANSCEND-T2D-1, was published in the Lancet in 2026 (PMID 42250575, NCT06354660); the TRIUMPH outcome data so far exists only as sponsor topline announcements, which have not been through journal peer review. TRIUMPH-1 toplines (sponsor press release, not yet peer-reviewed) report minus 28.3 percent body weight at 12 mg once weekly versus minus 2.2 percent on placebo at 80 weeks. Those figures have not been through journal peer review and remain provisional pending full publication; the PubMed searches NCT05929079 OR (retatrutide AND TRIUMPH-2) and NCT05882045 OR (retatrutide AND "TRIUMPH-3") identified only the design paper on 2026-09-18.

Did the trials test whether a longer titration reduces side effects?

The published data supports something narrower than that. It shows that a lower starting dose partially mitigated gastrointestinal events at the same target dose. It does not isolate the length or speed of escalation as an independent causal factor, because the trial was not designed to answer that question.

Where can I read the primary sources myself?

The Phase 2 obesity trial: Jastreboff AM et al., N Engl J Med 2023;389(6):514-526, PMID 37366315, registered NCT04881760. The Phase 1b pharmacokinetic trial: Urva S et al., Lancet 2022;400(10366):1869-1881, PMID 36354040. The TRIUMPH design paper: PMID 41090431. The comparator schedules come from the FDA prescribing information for Wegovy and Zepbound, both linked in the references below.

Which starting doses did the retatrutide trials use?

The Phase 2 obesity trial assigned 1, 4, 8 and 12 mg once weekly subcutaneously over 48 weeks, with 2 mg or 4 mg as the recorded starting dose in the escalating arms (PMID 37366315, NCT04881760). The Phase 2 diabetes trial used maintenance doses of 0.5, 4, 8 and 12 mg once weekly subcutaneously over 36 weeks (NCT04867785). Every Phase 3 or Phase 2b schedule for which a description exists, all of them once weekly subcutaneous, is described as beginning at 2 mg once weekly: in 537 adults with type 2 diabetes over 40 weeks (press release, 19 March 2026, NCT06354660), in 1,152 participants with type 2 diabetes and obesity and 1,949 participants with severe obesity and cardiovascular disease over 80 weeks (press release, 23 July 2026, NCT05929079, NCT05882045), and in 146 adults with chronic kidney disease over 24 weeks (PMID 41160422, NCT05936151). No retatrutide registry record names a 2.5 mg dose or step (ClinicalTrials.gov, query retatrutide, 34 records, 2026-09-18). These are study arms, not an application protocol.

How did the Phase 3 trials reach their target doses?

The TRIUMPH design paper reports a fixed, blinded dose escalation regimen, with 16 weeks of escalation then 64 weeks of maintenance in the 80-week once weekly subcutaneous trials (PMID 41090431). The sponsor describes the TRIUMPH-2 schedule in 1,152 participants with type 2 diabetes and obesity, and the TRIUMPH-3 schedule in 1,949 participants with severe obesity and cardiovascular disease, both once weekly subcutaneously over 80 weeks, as beginning at 2 mg once weekly with a step every four weeks to the randomised target dose (press release, 23 July 2026, not peer-reviewed; NCT05929079, NCT05882045). The TRANSCEND-CKD design paper reports the same four-week interval in 146 adults over 24 weeks (PMID 41160422, NCT05936151).

Has any trial compared different escalation schemes against each other?

The Phase 2 obesity trial compared different starting doses at the same target dose but not different escalation speeds (PMID 37366315, NCT04881760). A Phase 3b trial of three different retatrutide dose escalation schemes in an estimated 600 adults without type 2 diabetes, with no placebo arm and a primary endpoint at Week 104, is registered, active, not recruiting, with no posted results, and the registry does not say what the three schemes are (NCT07357415; ClinicalTrials.gov, query retatrutide, 2026-09-18). The PubMed searches retatrutide AND (escalation speed OR slower escalation OR faster escalation) and NCT07357415 OR (retatrutide AND "TRIUMPH-9") returned 0 records each on 2026-09-18.

What do the trials do with the dose after the escalation period?

The 80-week TRIUMPH trials are structured as 16 weeks of dose escalation followed by 64 weeks of maintenance, and the design paper reports that a permanent dose reduction is permitted for gastrointestinal adverse events after a de-escalation and re-escalation attempt (PMID 41090431). A Phase 3b trial in an estimated 643 participants randomises them, after an 80-week lead-in on one retatrutide dose, to stay on that dose, move to a second dose, or switch to placebo for 36 weeks, with a secondary endpoint at Week 116 and no posted results (NCT06859268). A long-term outcome trial describes escalation up to a maximum tolerated dose over about 248 weeks (NCT06383390, no posted results; ClinicalTrials.gov, query retatrutide, 2026-09-18).

Retatrutide Dose Escalation in Clinical Trials: What Was Measured

Q: Why did the trial start at a low dose instead of the target dose?

Tolerability is the stated rationale for stepwise escalation across this drug class. What the Phase 2 publication actually establishes is narrower: gastrointestinal events were dose-related and "were partially mitigated with a lower starting dose". So the evidence is about the starting dose, not about the escalation speed; the trial never compared escalation speeds against each other.

Retatrutide (LY-3437943) is an investigational once-weekly triple-hormone receptor agonist that activates GLP-1, GIP, and glucagon receptors. Published clinical data describe a structured dose-escalation approach used during treatment initiation. This article summarises dosing and pharmacokinetic points from the published retatrutide studies, including the first peer-reviewed Phase 3 trial (PMID 42250575, NCT06354660), and compares them with the labelled escalation schedules for semaglutide and tirzepatide.

Pharmacokinetics of Retatrutide

Published Phase 1 and Phase 2 studies support once-weekly subcutaneous dosing. Specific pharmacokinetic estimates such as half-life and dose proportionality come from the early multiple-ascending-dose study rather than from the obesity Phase 2 paper.

Parameter	Value	Source
Half-life (t1/2)	Approximately 6 days	Urva et al., Lancet 2022
Route of administration	Subcutaneous injection	Urva et al., Lancet 2022; Jastreboff et al., NEJM 2023; Lilly FAQ
Dosing interval	Once weekly in published Phase 1b and Phase 2 trials	Urva et al., Lancet 2022; Jastreboff et al., NEJM 2023; Lilly FAQ
Exposure	Dose-proportional pharmacokinetics in the Phase 1b study	Urva et al., Lancet 2022

Half-life (t1/2)

Value: Approximately 6 days
Source: Urva et al., Lancet 2022

Route of administration

Value: Subcutaneous injection
Source: Urva et al., Lancet 2022; Jastreboff et al., NEJM 2023; Lilly FAQ

Dosing interval

Value: Once weekly in published Phase 1b and Phase 2 trials
Source: Urva et al., Lancet 2022; Jastreboff et al., NEJM 2023; Lilly FAQ

Exposure

Value: Dose-proportional pharmacokinetics in the Phase 1b study
Source: Urva et al., Lancet 2022

The approximately 6-day half-life is consistent with a weekly schedule. In the escalation arms of the obesity Phase 2 trial the dose was raised stepwise to the assigned target over the first months of treatment; that trial should be cited for its design rather than as the primary source of the pharmacokinetic estimates above.

Dose Escalation in the Published Trials

The randomized Phase 2 obesity trial (Jastreboff AM et al., N Engl J Med 2023, PMID 37366315, registered as NCT04881760) randomised participants to target doses of 1 mg, 4 mg, 8 mg or 12 mg once weekly subcutaneously, reached either directly or by stepwise escalation from a lower starting dose during the first months of the 48-week treatment period; the registry's own results record states that dose escalation to improve gastrointestinal tolerability occurred in certain treatment groups up to Week 12 (NCT04881760). The registry records the individual escalation sequences per arm; this article does not reproduce them. Those are randomised study arms, not an application protocol.

This escalation design was used in a clinical trial setting. In the Phase 2 report, gastrointestinal adverse events were dose-related and were partially mitigated by a lower starting dose.

Target Doses and Starting Doses in the Phase 2 Trial

The arms differed in target dose and in starting dose: the 4 mg target was reached either directly or from a 2 mg start, the 8 mg target from a 2 mg or a 4 mg start, and the 12 mg target from a 2 mg start (NCT04881760, PMID 37366315). That design separates the effect of the target dose from the effect of the starting dose to some degree, which is what the tolerability finding below rests on. The step sequences and their timing are part of the trial registration and are not reproduced here; they describe randomised study arms, not an application protocol.

Starting Dose and Tolerability

The published retatrutide studies, like the approved semaglutide and tirzepatide labels, use gradual escalation rather than immediate full-dose exposure. Tolerability is the stated rationale. Be precise about what the data shows here: the Phase 2 publication reports that gastrointestinal events were dose-related and "were partially mitigated with a lower starting dose" (PMID 37366315). The trial did not compare escalation speeds against each other, so the independent effect of escalation speed was not tested there; a Phase 3b trial of three different retatrutide dose escalation schemes in an estimated 600 participants without type 2 diabetes is registered, active and not recruiting, with no posted results and no publication identified (NCT07357415; ClinicalTrials.gov, query retatrutide, 2026-09-18; PubMed search NCT07357415 OR (retatrutide AND "TRIUMPH-9"), 2026-09-18).

Gastrointestinal Tolerability

In the Phase 2 trial, the most commonly reported adverse events were gastrointestinal, including:

nausea
diarrhea
vomiting
constipation

In the published Phase 2 abstract, these events were described as dose-related, mostly mild to moderate, and partially mitigated with a lower starting dose. This article does not repeat exact event percentages because those figures depend on the analysis population, dose arm, and time window used in the source publication.

Mechanistic Context

Retatrutide engages three metabolic signalling pathways, one more than tirzepatide and two more than semaglutide. That is a mechanistic difference, and it does not by itself establish anything about tolerability. What is documented is simply the design: the Phase 2 trial used gradual up-titration rather than immediate exposure to the highest dose.

The Supposed Glucagon Threshold: What the Dose-Response and Appetite Data Show

Two claims circulate about a supposed threshold dose: that retatrutide's glucagon receptor arm only switches on above a certain weekly dose, leaving lower doses to the GLP-1 and GIP arms, and that appetite suppression fades above it. The published record establishes neither.

In vitro the molecule "shows balanced GCGR and GLP-1R activity but more GIPR activity" (Coskun T et al., Cell Metab 2022, PMID 35985340). That is relative potency, not an on/off point. The same paper's body weight finding, "augmented by the addition of GCGR-mediated increases in energy expenditure to GIPR- and GLP-1R-driven calorie intake reduction", is from obese mice. As of 2026-09-18, no completed study has reported a milligram dose at which glucagon receptor activity begins for this investigational compound (PubMed searches: 'retatrutide AND (threshold OR receptor occupancy)' and '(retatrutide OR LY3437943) AND threshold[tiab]', both returning only PMID 42649514; ClinicalTrials.gov search: 'retatrutide AND glucagon AND threshold', no studies).

The 4 mg figure fits the dose grid better than the biology. The phase 2 type 2 diabetes trial randomized maintenance doses of 0.5 mg, 4 mg, 8 mg and 12 mg (Rosenstock J et al., Lancet 2023, PMID 37385280, NCT04867785), so nothing sits between 0.5 mg and 4 mg. In that population body weight decreased dose dependently at 36 weeks by 3.19% at 0.5 mg, 7.92% and 10.37% in the two 4 mg arms, 16.81% and 16.34% in the two 8 mg arms and 16.94% at 12 mg, against 3.00% on placebo. Only at 4 mg and greater were those decreases significantly greater than placebo. Its body composition substudy reported percent reduction from baseline in total fat mass at week 36 of 4.9% at 0.5 mg, 15.2% at 4 mg pooled, 26.1% at 8 mg pooled and 23.2% at 12 mg, against 4.5% on placebo (Coskun T et al., Lancet Diabetes Endocrinol 2025, PMID 40609566).

Below 4 mg the readouts are not blank. The liver-fat substudy of the phase 2 obesity trial (NCT04881760) reported a mean relative change in liver fat at 24 weeks of -42.9% at 1 mg against +0.3% on placebo, all doses P<0.001 versus placebo (Sanyal AJ et al., Nat Med 2024, PMID 38858523). That paper related those reductions to body weight, abdominal fat and metabolic measures, not to a named receptor.

The appetite half fares no better. In the phase 2 obesity trial, perceived hunger and disinhibition scores fell significantly more than placebo in every retatrutide dose group at weeks 24 and 48, p < 0.01 for all comparisons, and the decreases "generally appeared dose-dependent, particularly for disinhibition" (Kanu C et al., Diabetes Obes Metab 2025, PMID 40735804). Pre-specified exploratory analyses in 275 adults with type 2 diabetes reported greater improvements versus placebo in Eating Inventory Perceived Hunger and Disinhibition at 8 mg and 12 mg, weeks 24 and 36 (Kanu C et al., Diabetes Obes Metab 2025, PMID 40916752). Both are group means, not individual trajectories.

As of 2026-09-18, no completed study has reported human data separating the calorie-intake component from the energy-expenditure component (PubMed search: 'retatrutide AND ("energy expenditure" OR "indirect calorimetry" OR "resting metabolic rate")', 8 records; ClinicalTrials.gov search: 'retatrutide AND energy expenditure', 1 study). That study, NCT06313528, is a phase 1 trial with 85 participants, completed 26 August 2025, calorie intake primary and 24-hour energy expenditure secondary, no results posted.

Retatrutide remains investigational. In the phase 2 obesity trial participants were randomized to a fixed target dose rather than titrating to effect (NCT04881760), titration guided by appetite response was not a randomised comparison in that trial. The published evidence does not answer that question.

Appetite Around the Escalation Steps: What Was Measured and When

In the Phase 2 obesity trial, participants "completed the 51-item Eating Inventory at baseline, Weeks 24 and 48", so both on-treatment readings came after escalation had finished; perceived hunger and disinhibition scores fell more than placebo in all retatrutide dose groups at both visits (p < 0.01 for all comparisons); the authors note that "the lag in treatment effect for the 12 mg group may have resulted from the long dose titration" (PMID 40735804). In the Phase 2 type 2 diabetes study, Appetite Visual Analog Scale scores in 275 adults came after 24 and 36 weeks; retatrutide at 4 mg or higher produced greater reductions from baseline in overall appetite, hunger and prospective food consumption than placebo at Week 24 (all p <0.05), a pre-specified exploratory analysis (PMID 40916752). Both are group means at fixed visits, not within-person step comparisons.

As of 2026-09-18, no completed study has reported appetite or hunger ratings measured before and after an individual retatrutide dose-escalation step (PubMed search: retatrutide AND (appetite OR hunger) AND ("dose escalation" OR titration), 0 records; ClinicalTrials.gov search: retatrutide, 34 registered studies, outcomes screened for appetite, hunger, eating and food-intake terms). NCT06313528 lists an appetite endpoint in a Phase 1 calorie-intake and energy-expenditure trial in 85 participants under calorie restriction, completed 26 August 2025, with no results posted.

Two adjacent findings are documented, neither of them a measurement around an escalation step:

Energy deficit: in 50 overweight or obese patients on a 10-week very-low-energy diet, no drug, mean weight loss was 13.5 kg (SE 0.5), subjective appetite rose at 10 weeks (P<0.001), and hunger differed from baseline at 62 weeks (PMID 22029981); our weight regain article covers this counter-regulation.
Glucagon-receptor arm: in obese mice, weight loss "was augmented by the addition of GCGR-mediated increases in energy expenditure to GIPR- and GLP-1R-driven calorie intake reduction" (PMID 35985340), preclinical, not a human measure of a step up.

The published record reports no use of appetite ratings as an input to the escalation sequence; the sequence was assigned by arm (NCT04881760).

Approved Labels versus Trial Regimen: Semaglutide, Tirzepatide, Retatrutide

The approved semaglutide and tirzepatide products carry their own label schedules, which are documented in their prescribing information. Retatrutide's published schedule now comes from the Phase 2 study arms described above, from the sponsor's description of the first peer-reviewed Phase 3 trial (press release, 19 March 2026; PMID 42250575, NCT06354660) and from a peer-reviewed Phase 2b design paper that reports the schedule in full (PMID 41160422, NCT05936151), and the compound remains investigational; the two kinds of source should be cited separately and read on their own terms.

This section compares the two kinds of source only, not efficacy. Retatrutide also remains investigational. The sponsor states that retatrutide is an investigational molecule that cannot legally be sold or marketed for use in humans, and that it is legally available only to participants in its clinical trials (press releases, 23 July 2026 and 15 September 2026).

What Changed in the Record by September 2026

The schedules below are study arms of the cited trials, not an application protocol.

Fourteen Phase 3 studies, none with posted results, and what their arms say about escalation

A ClinicalTrials.gov search for retatrutide on 2026-09-18 returned 34 registered studies, of which 14 are Phase 3, and all 14 have no posted results. Every Phase 3 arm is once weekly subcutaneous, and no Phase 3 registry record names a milligram value; the arms read Dose 1, 2 or 3, or Dose Escalation 1, 2 or 3, so milligram figures for those trials come from sponsor releases or published papers (NCT05929066, NCT05929079).

TRIUMPH-9 compares three retatrutide dose escalation schemes in an estimated 600 participants without type 2 diabetes, with no placebo arm and a primary endpoint at Week 104; the registry does not say what the three schemes are, and the trial is active, not recruiting, with no posted results (NCT07357415). TRIUMPH-6 describes an 80-week lead-in on one retatrutide dose, then a 36-week randomised phase in which an estimated 643 participants stay on that dose, move to a second dose, or switch to placebo (NCT06859268, no posted results). TRIUMPH-Outcomes describes escalated doses of retatrutide administered subcutaneously up to a maximum tolerated dose over about 248 weeks (NCT06383390, 10,000 estimated, no posted results; ClinicalTrials.gov, query retatrutide, 2026-09-18).

The first peer-reviewed Phase 3 schedule, and the first peer-reviewed escalation interval

TRANSCEND-T2D-1 randomised 537 adults with type 2 diabetes to retatrutide 4 mg, 9 mg or 12 mg or placebo, once weekly subcutaneously over 40 weeks; discontinuations due to adverse events were 2 to 5 percent with retatrutide and 0 percent with placebo (PMID 42250575, NCT06354660). The paper's abstract does not print the escalation schedule. The sponsor's own description of the 40-week once weekly subcutaneous schedule in 537 adults with type 2 diabetes (NCT06354660) has it beginning at 2 mg once weekly with a step every four weeks to the randomised target dose, and describes gastrointestinal events as having "occurred primarily during dose escalation" (press release, 19 March 2026, not peer-reviewed).

The TRIUMPH design paper reports a fixed, blinded dose escalation regimen, with 16 weeks of escalation then 64 weeks of maintenance in the 80-week trials (PMID 41090431). A Phase 2b design paper in 146 adults with chronic kidney disease, over 24 weeks of once weekly subcutaneous treatment, reports that retatrutide was initiated at 2 mg once weekly and that the dose was raised every four weeks until the randomisation dose was reached, with lower doses allowed where the top dose was not tolerated; it carries no outcome results (PMID 41160422, NCT05936151).

What the July 2026 announcements added, in reported form

The 23 July 2026 sponsor topline, not peer-reviewed, describes TRIUMPH-2 as 1,152 participants with type 2 diabetes and obesity randomised to retatrutide 4 mg, 9 mg or 12 mg or placebo once weekly subcutaneously over 80 weeks, and TRIUMPH-3 as 1,949 participants with severe obesity and established cardiovascular disease randomised to retatrutide 9 mg, 12 mg or placebo on the same route and duration (press release, 23 July 2026, NCT05929079, NCT05882045). It describes both schedules, in those 1,152 and 1,949 participants treated once weekly subcutaneously over 80 weeks, as beginning at 2 mg once weekly with a step every four weeks to the randomised target dose, and reports adverse-event discontinuations of 3.8 to 11.6 percent across the retatrutide arms of TRIUMPH-2 against 4.9 percent on placebo, and of 9.8 and 13.5 percent at 9 mg and 12 mg against 4.8 percent on placebo in TRIUMPH-3 (press release, 23 July 2026; NCT05929079, NCT05882045).

The Phase 2 obesity trial's results record, in 338 randomised participants assigned to treatment once weekly subcutaneously over 48 weeks, states that dose escalation to improve gastrointestinal tolerability occurred in certain treatment groups up to Week 12 (NCT04881760).

What the record still does not contain

PubMed searches (retatrutide OR LY3437943) AND ("exposure-response" OR "population pharmacokinetic" OR "popPK"), retatrutide AND (escalation speed OR slower escalation OR faster escalation), NCT07357415 OR (retatrutide AND "TRIUMPH-9"), and NCT06859268 OR (retatrutide AND "TRIUMPH-6") returned 0 records each on 2026-09-18; the Phase 2 obesity trial's participant-flow module records whole-study discontinuation by arm, not discontinuation during escalation (NCT04881760).

Scope of the Published Evidence

The published retatrutide sources cited here support two narrow points relevant to dosing:

published clinical studies used once-weekly subcutaneous administration
the Phase 2 obesity trial and the Phase 3 trials used stepwise escalation to the assigned target dose, which the programme's design paper describes as a fixed escalation regimen with participants and study staff blinded (PMID 41090431)

Broader operational details should come from study-specific documents, manufacturer materials, and institutional procedures rather than from inference based on the published trial papers alone.

Conclusion

The published retatrutide evidence supports a once-weekly, stepwise escalation approach in clinical research: the Phase 2 obesity trial arms, treated once weekly subcutaneously over 48 weeks, reached their randomised target doses of 1 to 12 mg either directly or by stepwise escalation from a lower starting dose (study arms, NCT04881760), and the first peer-reviewed Phase 3 trial randomised 537 adults with type 2 diabetes to 4 mg, 9 mg or 12 mg or placebo once weekly subcutaneously over 40 weeks (PMID 42250575, NCT06354660). The available sources also support cautious language: retatrutide remains investigational.

For schedule comparisons across the incretin field, approved product labels and investigational trial regimens should be cited separately and interpreted on their own terms.

This article is intended solely for informational purposes in scientific research. It does not provide medical advice and does not describe an approved prescribing protocol.

Frequently Asked Questions

References

Urva S, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022;400(10366):1869-1881. PMID 36354040.
Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. PMID 37366315. ClinicalTrials.gov NCT04881760.
Eli Lilly and Company. What to know about retatrutide.
U.S. FDA. Wegovy prescribing information.
U.S. FDA. Zepbound prescribing information.
Coskun T, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234-1247.e9. PMID 35985340.
Rosenstock J, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023;402(10401):529-544. PMID 37385280.
Coskun T, et al. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. Lancet Diabetes Endocrinol. 2025;13(8):674-684. PMID 40609566.
Kanu C, et al. Association between patient-reported eating behaviours and weight change: Secondary analyses of a randomized, double-blind trial comparing retatrutide and placebo in people with obesity or overweight. Diabetes Obes Metab. 2025;27(10):6088-6091. PMID 40735804.
Kanu C, et al. Appetite, eating attitudes, and eating behaviours during treatment with retatrutide in adults with type 2 diabetes: Results of a phase 2 study. Diabetes Obes Metab. 2025;27(12):6988-6998. PMID 40916752.
ClinicalTrials.gov. NCT06313528: A Randomized, Double-Blind, Phase 1 Study to Investigate the Effect of LY3437943 Versus Placebo on Calorie Intake and Energy Expenditure in Participants With Obesity Under Calorie Restriction.
Bajaj HS, et al. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. Lancet. 2026;407(10546):2402-2413. PMID 42250575. ClinicalTrials.gov NCT06354660.
Heerspink HJL, et al. Rationale, design and baseline characteristics of the TRANSCEND-CKD trial of retatrutide in patients with chronic kidney disease. Nephrol Dial Transplant. 2026. PMID 41160422. ClinicalTrials.gov NCT05936151.